



**Hing C. Wong, Ph.D.,
Founder, President & Chief Executive Officer
Altor BioScience Corporation**

Dr. Wong has served as the President & CEO of Altor since its inception in 2002. Prior to joining Altor, Dr. Wong founded Sunol Molecular Corporation in March 1996, becoming its President and Chief Executive Officer. He engineered the acquisition of the plant technology-based company, Xios, in April 2002 and the spin-off of Altor BioScience Corporation in August 2002. In 2004 and 2005, Dr. Wong led the successful sales of Sunol's tissue factor antagonist program and the anti-shigatoxin program to Tanox Inc. and Caprion Inc., respectively. After the sale of Sunol, he resigned from the executive office of Sunol to fully focus on development and advancement of Altor BioScience. During his tenures with Sunol and Altor, he raised over \$55 million in capital via equity and debt placements, set up many major pharmaceutical/biopharmaceutical partnerships/collaborations, and managed multiple clinical trials. He is the principal investigator of multiple NIH grants and an inventor of numerous issued US and worldwide patents, and he continues to publish scientific papers in peer-reviewed journals. He was a member of the Board of Directors of Sunol and Biosynexus, Inc. and was on the Board of Trustees for the Rumbaugh-Goodwin Institute for Cancer Research. Dr. Wong spearheaded the merger of the Rumbaugh-Goodwin Institute for Cancer Research and Nova Southeast University. Dr. Wong was the Director of the Department of Microbial Genetics at Cetus/Chiron Corporation from 1989-1992 and the Director of the Biology Skill Center of Baxter International from 1992-1996. During his tenure with Cetus/Chiron and Baxter, he made major contributions to the development of the approved drugs Proleukin® and Betaseron and led the product development team and commercialization of Innovin, Troponin I, Glucose Isomerase and Cellulon®. He received his Ph.D. degree in Microbiology and Immunology at the University Massachusetts, Amherst and conducted postdoctoral studies at the University of Washington in Seattle.